Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387270167> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4387270167 abstract "Introduction: Membrane-released arachidonic acid (AA) is metabolized via cyclooxygenase pathway to form prostanoids, including thromboxane, prostacyclin and prostaglandin E2. Aspirin suppresses platelet synthesis of thromboxane, rendering its first-line use for anti-thrombosis in patients with acute myocardial ischemia. We report that endogenous PGE2 protects against myocardial ischemia-reperfusion (MI/R) injury (Nat Commun. 2019;10(1):1888). The impact of AA administration while suppressing thromboxane on MI/R injury is unknown. Methods and Results: C57BL/6J mice were treated intravenously with vehicle, AA, aspirin, or their combination and then subjected to 30min coronary artery ligation and 24hr reperfusion. Cardiac function was assessed by ultrasonography and infraction size quantified by TTC staining. Cardiac microcirculation was assessed by laser doppler flow and vasomotor reactivity determined with isolated coronary arteries. Single treatment with AA at an optimized dose of 0.1mg/Kg, or combined with aspirin at a dose of 10mg/Kg that allowed sufficient suppressing of platelet activation over 24hr, decreased infarct size and improved heart function. Impressively, combination of AA with aspirin provided additional cardioprotection compared with either single treatment. While aspirin, not AA, ameliorated microvascular obstruction following MI/R injury, co-administration of AA and aspirin further increased coronary microcirculatory blood perfusion with improved vascular permeability compared with aspirin alone. MI/R impaired endothelium-dependent dilatation of coronary arteries, and the dual treatment, not AA or ASA alone, increased coronary artery relaxation. Cardiac infiltrated neutrophils and platelet-neutrophil aggregates were also reduced by the combination treatment, consistent with a suppressed leukocyte-ECs adhesion as assessed in vitro. Conclusions: AA and aspirin synergistically protect against MI/R injury and this is attributable to suppressed neutrophil inflammation and improved microvascular obstruction. AA might be used as an adjunct therapy to aspirin in patients with acute myocardial infarction." @default.
- W4387270167 created "2023-10-03" @default.
- W4387270167 creator A5005865028 @default.
- W4387270167 creator A5026142247 @default.
- W4387270167 creator A5061082958 @default.
- W4387270167 date "2023-05-01" @default.
- W4387270167 modified "2023-10-03" @default.
- W4387270167 title "Abstract 424: Arachidonic Acid Synergizes With Aspirin In Cardioprotection Following Acute Myocardial Infarction" @default.
- W4387270167 doi "https://doi.org/10.1161/atvb.43.suppl_1.424" @default.
- W4387270167 hasPublicationYear "2023" @default.
- W4387270167 type Work @default.
- W4387270167 citedByCount "0" @default.
- W4387270167 crossrefType "journal-article" @default.
- W4387270167 hasAuthorship W4387270167A5005865028 @default.
- W4387270167 hasAuthorship W4387270167A5026142247 @default.
- W4387270167 hasAuthorship W4387270167A5061082958 @default.
- W4387270167 hasConcept C126322002 @default.
- W4387270167 hasConcept C164705383 @default.
- W4387270167 hasConcept C181199279 @default.
- W4387270167 hasConcept C185592680 @default.
- W4387270167 hasConcept C2776785769 @default.
- W4387270167 hasConcept C2777628954 @default.
- W4387270167 hasConcept C2778078955 @default.
- W4387270167 hasConcept C2779676291 @default.
- W4387270167 hasConcept C2779689624 @default.
- W4387270167 hasConcept C2781024287 @default.
- W4387270167 hasConcept C2781128415 @default.
- W4387270167 hasConcept C42219234 @default.
- W4387270167 hasConcept C500558357 @default.
- W4387270167 hasConcept C55493867 @default.
- W4387270167 hasConcept C71924100 @default.
- W4387270167 hasConcept C89560881 @default.
- W4387270167 hasConceptScore W4387270167C126322002 @default.
- W4387270167 hasConceptScore W4387270167C164705383 @default.
- W4387270167 hasConceptScore W4387270167C181199279 @default.
- W4387270167 hasConceptScore W4387270167C185592680 @default.
- W4387270167 hasConceptScore W4387270167C2776785769 @default.
- W4387270167 hasConceptScore W4387270167C2777628954 @default.
- W4387270167 hasConceptScore W4387270167C2778078955 @default.
- W4387270167 hasConceptScore W4387270167C2779676291 @default.
- W4387270167 hasConceptScore W4387270167C2779689624 @default.
- W4387270167 hasConceptScore W4387270167C2781024287 @default.
- W4387270167 hasConceptScore W4387270167C2781128415 @default.
- W4387270167 hasConceptScore W4387270167C42219234 @default.
- W4387270167 hasConceptScore W4387270167C500558357 @default.
- W4387270167 hasConceptScore W4387270167C55493867 @default.
- W4387270167 hasConceptScore W4387270167C71924100 @default.
- W4387270167 hasConceptScore W4387270167C89560881 @default.
- W4387270167 hasIssue "Suppl_1" @default.
- W4387270167 hasLocation W43872701671 @default.
- W4387270167 hasOpenAccess W4387270167 @default.
- W4387270167 hasPrimaryLocation W43872701671 @default.
- W4387270167 hasRelatedWork W1967993738 @default.
- W4387270167 hasRelatedWork W2016980993 @default.
- W4387270167 hasRelatedWork W2073609370 @default.
- W4387270167 hasRelatedWork W2076598828 @default.
- W4387270167 hasRelatedWork W2077647736 @default.
- W4387270167 hasRelatedWork W2166497642 @default.
- W4387270167 hasRelatedWork W2311752599 @default.
- W4387270167 hasRelatedWork W2317069681 @default.
- W4387270167 hasRelatedWork W2395515329 @default.
- W4387270167 hasRelatedWork W2884644605 @default.
- W4387270167 hasVolume "43" @default.
- W4387270167 isParatext "false" @default.
- W4387270167 isRetracted "false" @default.
- W4387270167 workType "article" @default.